These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30031975)

  • 1. Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors.
    Talapatra SK; Tham CL; Guglielmi P; Cirilli R; Chandrasekaran B; Karpoormath R; Carradori S; Kozielski F
    Eur J Med Chem; 2018 Aug; 156():641-651. PubMed ID: 30031975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel thiadiazole-thiazolone hybrids as potential inhibitors of the human mitotic kinesin Eg5.
    Khathi SP; Chandrasekaran B; Karunanidhi S; Tham CL; Kozielski F; Sayyad N; Karpoormath R
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2930-2938. PubMed ID: 30055887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinesin Eg5 Targeting Inhibitors as a New Strategy for Gastric Adenocarcinoma Treatment.
    Marconi GD; Carradori S; Ricci A; Guglielmi P; Cataldi A; Zara S
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31683688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells.
    Taglieri L; Rubinacci G; Giuffrida A; Carradori S; Scarpa S
    Invest New Drugs; 2018 Feb; 36(1):28-35. PubMed ID: 28965307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
    Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
    Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
    Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
    Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.
    De Iuliis F; Taglieri L; Salerno G; Giuffrida A; Milana B; Giantulli S; Carradori S; Silvestri I; Scarpa S
    Invest New Drugs; 2016 Aug; 34(4):399-406. PubMed ID: 26994617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.
    Makala H; Ulaganathan V
    J Recept Signal Transduct Res; 2018 Feb; 38(1):12-19. PubMed ID: 29041840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex.
    Kaan HY; Ulaganathan V; Hackney DD; Kozielski F
    Biochem J; 2009 Dec; 425(1):55-60. PubMed ID: 19793049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into a unique inhibitor binding pocket in kinesin spindle protein.
    Ulaganathan V; Talapatra SK; Rath O; Pannifer A; Hackney DD; Kozielski F
    J Am Chem Soc; 2013 Feb; 135(6):2263-72. PubMed ID: 23305346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells.
    Nicolai A; Taurone S; Carradori S; Artico M; Greco A; Costi R; Scarpa S
    Invest New Drugs; 2022 Jun; 40(3):556-564. PubMed ID: 35312942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5.
    Yokoyama H; Sawada J; Katoh S; Matsuno K; Ogo N; Ishikawa Y; Hashimoto H; Fujii S; Asai A
    ACS Chem Biol; 2015 Apr; 10(4):1128-36. PubMed ID: 25622007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
    De Monte C; Carradori S; Secci D; D'Ascenzio M; Guglielmi P; Mollica A; Morrone S; Scarpa S; Aglianò AM; Giantulli S; Silvestri I
    Eur J Med Chem; 2015 Nov; 105():245-62. PubMed ID: 26498571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5-Inhibitor Complexes.
    Indorato RL; Talapatra SK; Lin F; Haider S; Mackay SP; Kozielski F; Skoufias DA
    Mol Cancer Ther; 2019 Dec; 18(12):2394-2406. PubMed ID: 31488701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
    Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
    J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
    Garcia-Saez I; Skoufias DA
    Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
    Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
    Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells.
    Giantulli S; De Iuliis F; Taglieri L; Carradori S; Menichelli G; Morrone S; Scarpa S; Silvestri I
    Anticancer Drugs; 2018 Aug; 29(7):674-681. PubMed ID: 29738338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1,3,4-thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide to human isoform II.
    Menchise V; De Simone G; Di Fiore A; Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6204-8. PubMed ID: 17000110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships and molecular docking of novel dihydropyrimidine-based mitotic Eg5 inhibitors.
    Prokopcová H; Dallinger D; Uray G; Kaan HY; Ulaganathan V; Kozielski F; Laggner C; Kappe CO
    ChemMedChem; 2010 Oct; 5(10):1760-9. PubMed ID: 20737530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.